ENTX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:58):

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs...

Stats
今日成交量	25 263.00
平均成交量	233 156
市值	71.32M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $-0.0600 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.48
ATR14	$0.0260 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Yaacov-garbeli Dana	Buy	130 000	Stock Option (right to buy)
2024-04-19	Yaacov-garbeli Dana	Buy	30 151	Ordinary Shares, par value NIS 0.0000769 per share
2024-04-19	Galitzer Hillel	Buy	130 000	Stock Option (right to buy)
2024-04-19	Galitzer Hillel	Buy	30 151	Ordinary Shares, par value NIS 0.0000769 per share
2024-01-12	Taitel Haya	Buy	9 500	Ordinary Shares, par value NIS 0.0000769 per share

INSIDER POWER
100.00
Last 93 transactions
Buy: 4 653 836 \| Sell: 4 161 674

音量相关性

長: -0.54 (weak negative)

短: 0.52 (weak)

Signal:(54.693) Neutral

Entera Bio Ltd 相关性

10 最正相关
TITN	0.854
TBLA	0.849
OPNT	0.84
OFIX	0.838
NAVI	0.835
LCAA	0.834
ATEC	0.831
ALSA	0.828
WDAY	0.827
GLLI	0.825

10 最负相关
AVO	-0.847
BLIN	-0.845
GETVV	-0.84
GLUE	-0.839
SIDU	-0.837
ATAI	-0.824
BIMI	-0.819
CEG	-0.816
DRUG	-0.814
GPOR	-0.813

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Entera Bio Ltd 相关性 - 货币/商品

0.01
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.55
( weak )

-0.06
( neutral )

Entera Bio Ltd 财务报表

Annual	2023
营收:	$0
毛利润:	$-56 000.00 (0.00 %)
EPS:	$-0.310

FY	2023
营收:	$0
毛利润:	$-56 000.00 (0.00 %)
EPS:	$-0.310

FY	2022
营收:	$134 000
毛利润:	$33 000.00 (24.63 %)
EPS:	$-0.450

FY	2021
营收:	$571 000
毛利润:	$198 000 (34.68 %)
EPS:	$0.425

Financial Reports:

No articles found.

Entera Bio Ltd

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

实时更新： Entera Bio Ltd [ENTX]

Upcoming Earnings Alert